​
​

G1 Therapeutics (GTHX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

G1 Therapeutics Revenue Highlights

Latest Revenue (Y)

$82.51M

Latest Revenue (Q)

$16.55M

Main Segment (Y)

Product

G1 Therapeutics Revenue by Period

G1 Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$82.51M60.84%
2022-12-31$51.30M62.98%
2021-12-31$31.48M-30.49%
2020-12-31$45.28M100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31--100.00%
2015-12-31$522.00K-49.94%
2014-12-31$1.04M-

G1 Therapeutics generated $82.51M in revenue during NA 2023, up 60.84% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

G1 Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30$16.55M14.30%
2024-03-31$14.48M-2.67%
2023-12-31$14.87M20.92%
2023-09-30$12.30M-70.99%
2023-06-30$42.39M227.45%
2023-03-31$12.95M26.30%
2022-12-31$10.25M-56.52%
2022-09-30$23.58M122.98%
2022-06-30$10.57M53.19%
2022-03-31$6.90M19.08%
2021-12-31$5.80M19.31%
2021-09-30$4.86M-26.44%
2021-06-30$6.60M-53.55%
2021-03-31$14.22M-14.07%
2020-12-31$16.55M-37.79%
2020-09-30$26.60M1142.94%
2020-06-30$2.14M100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--100.00%
2018-12-31$103.21M100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31--

G1 Therapeutics generated $16.55M in revenue during Q2 2024, up 14.30% compared to the previous quarter, and up 127.81% compared to the same period a year ago.

G1 Therapeutics Revenue Breakdown

G1 Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20
Product$46.34M$31.34M$11.12M-
License$36.17M$19.96M$20.36M-
Cost Reimbursements---$1.30M

G1 Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (56.17%), and License (43.83%).

Quarterly Revenue by Product

Product/ServiceMar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Sep 20
Product$14.08M$13.92M$10.84M$11.09M$10.49M$8.87M$8.27M$8.72M$5.48M$4.40M$3.58M$2.53M$609.00K-
License$397.00K$951.00K$1.46M$31.30M$2.45M$1.38M$15.31M$1.85M$1.42M$1.39M$1.28M$4.07M$13.61M-
Cost Reimbursements-------------$600.00K

G1 Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (97.26%), and License (2.74%).

G1 Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
AMLXAmylyx Pharmaceuticals$380.79M$416.00K
AXSMAxsome Therapeutics$270.60M$87.17M
CHRSCoherus BioSciences$257.24M$70.77M
BPMCBlueprint Medicines$249.38M$128.18M
PBYIPuma Bio$235.64M$56.14M
SGMOSangamo Therapeutics$176.23M$356.00K
HRTXHeron Therapeutics$127.04M$36.02M
RCUSArcus Biosciences$117.00M$48.00M
GTHXG1 Therapeutics$82.51M$16.55M
FATEFate Therapeutics$63.53M$6.77M
MGNXMacroGenics$58.75M$110.71M
CRBUCaribou Biosciences$34.48M$3.46M
HOOKHOOKIPA Pharma$20.13M-
MREOMereo BioPharma Group$10.00M-
ATRAAtara Biotherapeutics$8.57M$40.19M
ALLOAllogene Therapeutics$95.00K-
XFORX4 Pharmaceuticals-$560.00K
PDSBPDS Bio--
DAWNDay One Biopharmaceuticals-$20.07M
ABOSAcumen Pharmaceuticals--
ANNXAnnexon--
LRMRLarimar Therapeutics--
SANASana Bio--

GTHX Revenue FAQ

What is G1 Therapeutics’s yearly revenue?

G1 Therapeutics's yearly revenue for 2023 was $82.51M, representing an increase of 60.84% compared to 2022. The company's yearly revenue for 2022 was $51.3M, representing an increase of 62.98% compared to 2021. GTHX's yearly revenue for 2021 was $31.48M, representing a decrease of -30.49% compared to 2020.

What is G1 Therapeutics’s quarterly revenue?

G1 Therapeutics's quarterly revenue for Q2 2024 was $16.55M, a 14.30% increase from the previous quarter (Q1 2024), and a -60.97% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $14.48M, a -2.67% decrease from the previous quarter (Q4 2023), and a 11.82% increase year-over-year (Q1 2023). GTHX's quarterly revenue for Q4 2023 was $14.87M, a 20.92% increase from the previous quarter (Q3 2023), and a 45.10% increase year-over-year (Q4 2022).

What is G1 Therapeutics’s revenue growth rate?

G1 Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 162.14%, and for the last 5 years (2019-2023) was 0%.

What are G1 Therapeutics’s revenue streams?

G1 Therapeutics's revenue streams in c 23 are Product, and License. Product generated $46.34M in revenue, accounting 56.17% of the company's total revenue, up 47.89% year-over-year. License generated $36.17M in revenue, accounting 43.83% of the company's total revenue, up 81.16% year-over-year.

What is G1 Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of G1 Therapeutics was Product. This segment made a revenue of $46.34M, representing 56.17% of the company's total revenue.